Currently, SM08502 is being evaluated in a Phase 1, open-label, multicenter, dose escalation study (NCT03355066) in 42 adult patients with advanced solid tumors for whom standard therapy is not available for their stage of diagnosis.
For patients with resected pancreatic cancer, adjuvant therapy with a modified regimen of chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin have a significantly longer survival compared with gemcitabine.
Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor, is being assessed in the ongoing Phase 3 POLO trial.
The Company is investigating the treatment as a combination with nab-paclitaxel (Abraxane; Celgene) for pancreatic cancers and other solid tumors.
LOXO-292 is being evaluated in the ongoing Phase 1/2 LIBRETTO-001 clinical trial.
Unlike most lesion medical image datasets currently available, which can detect only 1 type of lesion, DeepLesion has much diversity and contains critical radiology findings from across the body, including lung nodules, liver tumors, and enlarged lymph nodes.
Perineal use of talc-based body powder is classified as “possibly carcinogenic to humans.”
Infugem utilizes a novel technology that enables cytotoxic oncology products to be premixed in a sterile setting and to be supplied to prescribers in RTA infusion bags.
In the first 2 years after cancer diagnosis, the excess risk for diabetes was highest, and it remained elevated throughout follow-up.
Thierry Conroy, MD, from the Institut de Cancérologie de Lorraine in Vandœuvre-lès-Nancy, France, and colleagues randomized patients with histologically proven pancreatic ductal adenocarcinomas, 21 to 84 days after resection, to six cycles of gemcitabine (arm A; 246 patients) or 12 cycles of mFOLFIRINOX (arm B; 247 patients).
